We are live on ! Find out more
UOC

UBS O'Connor Portfolio holdings

AUM $3.38B
1-Year Est. Return 63.08%
This Fund
S&P 500
This Quarter Est. Return
+0.05%
1 Year Est. Return
+63.08%
3 Year Est. Return
+180.99%
5 Year Est. Return
+483.22%
10 Year Est. Return
+2,128.62%
AUM
$3.55B
AUM Growth
+$59.4M
Cap. Flow
+$77M
Cap. Flow %
2.17%
Top 10 Hldgs %
49.57%
Holding
665
New
156
Increased
155
Reduced
111
Closed
128

Top Buys

Rank Stock Value
1
HCP
HashiCorp, Inc. Class A Common Stock
HCP
+$138M
2
ETRN
Equitrans Midstream Corporation Common Stock
ETRN
+$131M
3
EDR
Endeavor Group Holdings, Inc.
EDR
+$127M
4
MRO
Marathon Oil Corporation
MRO
+$123M
5
CHX
ChampionX
CHX
+$98.3M

Top Sells

Rank Stock Value
1
PXD
Pioneer Natural Resource Co.
PXD
+$638M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$51.2M
3
DFS
Discover Financial Services
DFS
+$45.1M
4
SCRM
Screaming Eagle Acquisition Corp. Class A Ordinary Shares
SCRM
+$18.4M
5
NSC icon
Norfolk Southern
NSC
+$17.7M

Sector Composition

Rank Sector Weight
1 Energy 26.53%
2 Technology 21.03%
3 Healthcare 14.68%
4 Industrials 8.19%
5 Materials 6.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGM icon
301
PUT
MGM Resorts International
MGM
$11.2B
$870K 0.02%
250,000
+175,000
+233% +$7.31M
SHOP icon
302
Shopify
SHOP
$190B
$859K 0.02%
13,000
+6,500
+100% +$431K
RAMP icon
303
LiveRamp
RAMP
$2.3B
$851K 0.02%
27,500
-157,500
-85% -$5.06M
CATX icon
304
Perspective Therapeutics
CATX
$339M
$848K 0.02%
+85,013
New +$1.23M
TFX icon
305
Teleflex
TFX
$6.15B
$841K 0.02%
+4,000
New +$838K
RVNC
306
DELISTED
Revance Therapeutics, Inc.
RVNC
$836K 0.02%
325,314
+70,647
+28% +$241K
GTM
307
ZoomInfo Technologies
GTM
$1.21B
$830K 0.02%
+65,000
New +$909K
PLRX icon
308
Pliant Therapeutics
PLRX
$65M
$828K 0.02%
+77,000
New +$993K
TEVA icon
309
Teva Pharmaceuticals
TEVA
$40.6B
$827K 0.02%
50,896
+6,000
+13% +$92.4K
TCOM icon
310
Trip.com Group
TCOM
$29.1B
$823K 0.02%
17,500
-347,500
-95% -$17.7M
RGNX icon
311
Regenxbio
RGNX
$745M
$821K 0.02%
+70,199
New +$1.09M
SONO icon
312
Sonos
SONO
$1.83B
$812K 0.02%
55,000
+15,000
+38% +$249K
QURE icon
313
uniQure
QURE
$3.15B
$811K 0.02%
180,939
+109,875
+155% +$535K
ORIC icon
314
Oric Pharmaceuticals
ORIC
$1.34B
$809K 0.02%
114,366
+22,000
+24% +$197K
ARVN icon
315
Arvinas
ARVN
$568M
$807K 0.02%
30,301
-1,200
-4% -$38.2K
STRO icon
316
Sutro Biopharma
STRO
$400M
$806K 0.02%
27,506
+2,000
+8% +$79.1K
CNTB
317
Connect Biopharma Holdings
CNTB
$138M
$776K 0.02%
510,701
– –
RIGL icon
318
Rigel Pharmaceuticals
RIGL
$733M
$760K 0.02%
92,448
+25,173
+37% +$263K
MTCH icon
319
Match Group
MTCH
$8.4B
$760K 0.02%
25,000
-10,000
-29% -$316K
O icon
320
Realty Income
O
$59B
$755K 0.02%
+14,300
New +$764K
CRC icon
321
California Resources
CRC
$4.67B
$748K 0.02%
14,046
-490
-3% -$25K
AVB icon
322
AvalonBay Communities
AVB
$26.6B
$745K 0.02%
+3,600
New +$696K
ZM icon
323
Zoom
ZM
$29.7B
$740K 0.02%
12,500
-15,000
-55% -$921K
PODD icon
324
Insulet
PODD
$9.66B
$736K 0.02%
3,647
-5,200
-59% -$937K
DNLI icon
325
Denali Therapeutics
DNLI
$3.92B
$732K 0.02%
31,517
+6,484
+26% +$124K
11 12
13
14 15

Similar funds

FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
SAG
SageView Advisory Group Newport Beach, California $2.96B AUM 15.81% 1-Year Est. Return
ACI
Alpha Cubed Investments Irvine, California $2.92B AUM 31.27% 1-Year Est. Return
TCOV
Trust Company of Vermont Brattleboro, Vermont $2.4B AUM 18.8% 1-Year Est. Return
RC
RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return
A
AlphaQuest New York $1.79B AUM 10.61% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return
CB
Cadence Bank Tupelo, Mississippi $1.71B AUM 16.17% 1-Year Est. Return

UBS O'Connor's Q2 2024 Portfolio in Review

As of Q2 2024, UBS O'Connor held 665 positions worth $3.55B, up 1.7% from $3.49B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

UBS O'Connor's Q2 2024 filing shows 156 new, 155 increased, 111 reduced and 128 closed positions. Its largest new stake was Endeavor Group Holdings, Inc.: 4,789,930 shares worth $129M. The largest sale was Pioneer Natural Resource Co., an estimated $638M.

By sector, the portfolio is most concentrated in Energy at 27% of assets, down from 34% a quarter earlier, followed by Technology and Healthcare.

  • UBS O'Connor's largest Q2 2024 buy was Endeavor Group Holdings, Inc.: 4,789,930 shares worth $129M.
  • UBS O'Connor added most to HashiCorp, Inc. Class A Common Stock in Q2 2024, an estimated $138M increase.
  • UBS O'Connor's biggest Q2 2024 reduction was Cerevel Therapeutics Holdings, Inc. Common Stock, cutting an estimated $51.2M.
  • UBS O'Connor fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $638M.
  • UBS O'Connor's ten largest holdings make up 50% of its $3.55B portfolio in Q2 2024.
  • UBS O'Connor opened 156 new positions and closed 128 in Q2 2024.
  • UBS O'Connor's portfolio value rose 1.7% quarter-over-quarter to $3.55B.

Based on UBS O'Connor's 13F filing for Q2 2024, filed 14 Aug 2024.